Related Experiment Video
Updated: Jun 11, 2025
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
[Research progress on albumin therapy for hepatic encephalopathy]
1Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing 401336, China.
Insights
Hepatic encephalopathy (HE), a brain dysfunction in cirrhosis patients, is complex to treat. Human albumin shows promise as a safe and effective therapy, improving cognitive function and quality of life.
Area of Science:
- Hepatology
- Neurology
- Gastroenterology
Background:
- Hepatic encephalopathy (HE) is a severe complication of decompensated cirrhosis, characterized by neurological and psychiatric dysfunction.
- Pathogenesis involves complex factors including ammonia toxicity, oxidative stress, inflammation, and gut dysbiosis.
- Current treatments for HE lack specificity, with options like lactulose, rifaximin, and supportive therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of human albumin as a treatment for hepatic encephalopathy.
- To assess the impact of human albumin on cognitive function and quality of life in HE patients.
Main Methods:
- Review of recent research and clinical studies on human albumin therapy for HE.
- Analysis of treatment outcomes, including cognitive improvements and quality of life metrics.
Main Results:
- Human albumin demonstrated safety and effectiveness in treating hepatic encephalopathy.
- Significant improvements were observed in patients' cognitive function.
- Enhanced quality of life was reported in patients receiving human albumin treatment.
Conclusions:
- Human albumin represents a promising therapeutic option for hepatic encephalopathy.
- This treatment offers benefits beyond cognitive enhancement, positively impacting overall patient well-being.
- Further research may solidify human albumin's role in managing HE complications.
Abstract:
Hepatic encephalopathy (HE) is one of the severe complications of decompensated stage cirrhosis that causes cerebral dysfunction due to hepatic insufficiency and/or portosystemic shunts, and it usually manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. The pathogenesis of HE is complex, although ammonia toxicity, oxidative stress, inflammation, intestinal dysbiosis, and others among them mainly play an important role. The treatment for HE lacks specific drugs, and the current available drugs include non-absorbable disaccharides (lactulose), antibiotics (rifaximin), and other therapies (oral branched-chain amino acids, intravenous injection of L-ornithine-L-aspartic acid, probiotics). Recent research has shown that human albumin is a safe and effective treatment for HE, improving not only cognitive function but also enhancing patients' quality of life.
More Related Videos
07:22Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
Published on: November 8, 2017
09:44Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Related Concept Videos
01:29Drug Distribution: Plasma Protein Binding
01:24Nephrotic Syndrome III : Nursing Management
01:09Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...